Abstract:In clinical development, an independent data safety monitoring committee (IDMC) is often established to ensure the test treatment's integrity, quality, safety, and efficacy under investigation. In clinical trials, IDMC may recommend stopping the trial early due to safety, futility/efficacy, or both after reviewing observed data in the interim based on pre-specified stopping boundaries. In practice, the interim data is often too small to reach clinically meaningful differences with statistical significance (i.e., the observed clinically meaningful difference is reproducible and not purely by chance alone). To provide an overall assessment (or complete clinical picture) of the performance of the test treatment under investigation, the FDA (2023) published guidance on the benefit-risk assessment (BRA) framework to facilitate IDMC decision-making. Several methods have been studied in the literature following the FDA's recommended framework. However, these methods did not consider the uncertainties and heterogeneities. Alternatively, a BRA approach is proposed based on a confidence ellipse of primary safety and efficacy endpoints. The proposed confidence ellipse approach was evaluated both theoretically and via a clinical trial simulation. The results indicate that the proposed confidence ellipse provides consistent and stable metrics, particularly as sample sizes increase. The derived metrics of Benefit-Risk Difference (BRD) and Benefit-Risk Ratio (BRR) showed favorable performance across different scenarios and thresholds. Applied to the TESTING trial data, our method confirmed and extended the original finding that a reduced methylprednisolone dose offered a more favorable benefit-risk profile. Specifically, the confidence ellipse method highlighted that the reduced dose consistently provided a better balance between efficacy and safety, particularly under stricter criteria for clinical significance. This method validated the original conclusions and provided additional insights into how different dosing regimens perform across various clinical scenarios, potentially offering a more refined tool for optimizing treatment decisions in complex therapeutic contexts.

Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials

Risk-Based Quality Management: A Case for Centralized Monitoring

Efficient positioning of QTL and Secondary Limit thresholds in a clinical trial risk-based monitoring

Quality risk management and data integrity in R&D laboratories supporting CMC lifecycle of biological products

Mastering Quality: Uniting Risk Assessment With Quality by Design (QbD) Principles for Pharmaceutical Excellence

Survey of Risk-Based Quality Management Status and Establishment of Operational Model in Clinical Trials

A new risk and issue management system to improve productivity, quality, and compliance in clinical trials

Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations

Robust EM Continual Reassessment Method in Oncology Dose Finding

Exploring Data Quality Management within Clinical Trials

The Role of Quality Assurance in Clinical Trials: Safeguarding Data Integrity and Compliance

Quantitative Safety Monitoring in Clinical Trials: Application of Multiple Statistical Methodologies for Infrequent Events

Implementing a Risk-Based Approach to Quality Management System ISO-13485 Processes in Compliance with EUMDR 2017/745 for Medical Device Industry

Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist

FDA experiences with a centralized statistical monitoring tool

Advancing the Field of Pharmaceutical Risk Minimization Through Application of Implementation Science Best Practices

A Proposed Confidence Ellipse Approach for Benefit-Risk Assessment in Clinical Trials

A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry

A Risk-Based Assessment for Determining the Pharmacokinetic Comparability Requirements of Biologic-Device Combination Products Administered by Subcutaneous Injection

A Framework for Risk-Benefit Evaluations in Biomedical Research

Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-Making